Performance of exome sequencing for pharmacogenomics

Personalized Medicine

Volumn 12, Issue 2, 2015, Pages 109-115

  Londin, Eric R ^a   Clark, Peter ^b   Sponziello, Marialuisa ^c   Kricka, Larry J ^d   Fortina, Paolo ^a,e   Park, Jason Y ^f  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

exome sequencing; pharmacogenomics; warfarin

Indexed keywords

CYTOCHROME P450 2C9; GENOMIC DNA; SPACER DNA; WARFARIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; EXOME; EXON; FALSE NEGATIVE RESULT; GENE SEQUENCE; GENETIC CODE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; PERFORMANCE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROMOTER REGION;

EID: 84925964952     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.14.77     Document Type: Article

References (26)

1. Pharmg kb (2014). The Pharmacogenomics Knowledgebase. www.pharmgkb.org
2. Carlson CS, Reider MJ, Nickerson DA, Eberle MA, Kruglyak L. Comment on 'Discrepancies in dbSNP confirmations rates and allele frequency distributions from varying genotyping error rates and patterns'. Bioinformatics 21(2), 141-143 (2005
3. Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 13(5), 247-252 (2003
4. Amplichip. CYP450 Test (2014). http://molecular.roche.com/ assays/Pages/AmpliChipCYP450Test.aspx
5. Affymetrix. DMET Plus Solution (2014). www.affymetrix. com/estore/browse/level-three-category-and-children.jsp?ca tegory=35791&categoryIdClicked=35791&expand=true&pa rent=35923
6. Rumble SM, Lacroute P, Dalca AV, Fiume M, Sidow A, Brudno M. SHRiMP: accurate mapping of short color-space reads. PLoS Comput. Biol. 5(5), e1000386 (2009
7. Martin M. Cutadapt removes adapter sequences from highthroughput sequencing reads. EMBnet. journal 17, 10-12 (2011
8. Li H, Handsaker B, Wysoker A, et al. The sequence alignment/ map format and SAMtools. Bioinformatics 25(16), 2078-2079 (2009
9. Burmester JK, Sedova M, Shapero MH, Mansfield E. DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol. Biol. 632, 99-124 (2010
10. Deeken JF, Cormier T, Price DK, et al. A pharmacogenetic study of docetaxel and thalidomide in patients with castrationresistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J. 10(3), 191-199 (2010
11. Sissung TM, English BC, Venzon D, Figg WD, Deeken JF. Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics 11(1), 89-103 (2010
12. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90(4), 625-629 (2011
13. Asan, Xu Y, Jiang H, et al. Comprehensive comparison of three commercial human whole-exome capture platforms. Genome Biol. 12(9), R95 (2011
14. Meynert AM, Bicknell LS, Hurles ME, Jackson AP, Taylor MS. Quantifying single nucleotide variant detection sensitivity in exome sequencing. BMC Bioinformatics 14, 195 (2013
15. Yang Y, Muzny DM, Reid JG, et al. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. N. Engl. J. Med. 369(16), 1502-1511 (2013
16. NHLBI. Exome Sequencing Project (ESP) (2014). http://evs. gs.washington.edu/EVS/
17. De Gregori M, Garbin G, De Gregori S, et al. Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain. Eur. J. Clin. Pharmacol. 69(9), 1651-1658 (2013
18. Agundez JA, Garcia-Martin E, Alonso-Navarro H, Jimenez-Jimenez FJ. Anti-Parkinson's disease drugs and pharmacogenetic considerations. Expert Opin. Drug Metab. Toxicol. 9(7), 859-874 (2013
19. Jung JA, Lim HS. Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-Analysis. Pharmacogenomics 15(1), 49-60 (2014
20. Martinez De Duenas E, Ochoa Aranda E, Blancas Lopez-Barajas I, et al. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype. Breast 23(4), 400-406 (2014
21. Langaee TY, Zhu HJ, Wang X, et al. The influence of the CYP2C19 10 allele on clopidogrel activation and CYP2C19 2 genotyping. Pharmacogenet. Genomics 24(8), 381-386 (2014
22. Tatarunas V, Jankauskiene L, Kupstyte N, et al. The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy. Blood Coagul. Fibrinolysis 25(4), 369-374 (2014
23. Canestaro WJ, Austin MA, Thummel KE. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genet. Med. 16(11), 810-819 (2014
24. De Keyser CE, Peters BJ, Becker ML, et al. The SLCO1B1 c.521TC polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenet. Genomics 24(1), 43-51 (2014
25. Rasmussen-Torvik LJ, Stallings SC, Gordon AS, et al. Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin. Pharmacol. Ther. 96(4), 482-489 (2014
26. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489(7414), 57-74 (2012